Literature DB >> 3892914

Pathogenesis of impaired glucose tolerance and type II diabetes mellitus--current status.

M B Davidson.   

Abstract

The insulin response to glucose taken orally is increased in patients with impaired glucose tolerance (IGT) but decreased in those with type II diabetes mellitus. The insulin response to meals, however, is normal in patients with type II diabetes, although the glucose concentrations are obviously elevated. The acute insulin response to intravenously administered glucose is absent in cases of both IGT and type II diabetes when the fasting plasma glucose level exceeds 115 mg per dl. On the other hand, the response to other intravenously given secretagogues is either normal or nearly so. The absent acute insulin response to intravenously administered glucose can be restored by alpha-adrenergic blockade, prostaglandin synthesis inhibition, dopaminergic blockade and euglycemia. Insulin antagonism characterizes patients with both IGT and type II diabetes. Those with IGT and mild diabetes mellitus (untreated fasting plasma glucose concentrations < 180 mg per dI) have a receptor defect probably due to down regulation. Diabetic patients with more severe type II diabetes show a postreceptor defect. The relation (if any) between receptor and postreceptor defects is unclear.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3892914      PMCID: PMC1305982     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  91 in total

1.  Insulin interactions with its receptors: experimental evidence for negative cooperativity.

Authors:  P de Meyts; J Roth; D M Neville; J R Gavin; M A Lesniak
Journal:  Biochem Biophys Res Commun       Date:  1973-11-01       Impact factor: 3.575

2.  Quantitative aspects of the insulin-receptor interaction in liver plasma membranes.

Authors:  C R Kahn; P Freychet; J Roth; D M Neville
Journal:  J Biol Chem       Date:  1974-04-10       Impact factor: 5.157

3.  Further evidence that insulin resistance exists in patients with chemical diabetes.

Authors:  H Ginsberg; J M Olefsky; G M Reaven
Journal:  Diabetes       Date:  1974-08       Impact factor: 9.461

4.  Basal and stimulated insulin levels: comparison of insulinogenic effects of oral glucose and intravenous tolbutamide in nondiabetic and diabetic subjects.

Authors:  J D Bagdade; E L Bierman; D Porte
Journal:  Metabolism       Date:  1971-11       Impact factor: 8.694

5.  Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes.

Authors:  S W Shen; G M Reaven; J W Farquhar
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

6.  Insulin response to glucagon. The opposing effects of diabetes and obesity.

Authors:  P M Crockford; W R Hazzard; R H Williams
Journal:  Diabetes       Date:  1969-04       Impact factor: 9.461

7.  The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects.

Authors:  J D Bagdade; E L Bierman; D Porte
Journal:  J Clin Invest       Date:  1967-10       Impact factor: 14.808

8.  Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture.

Authors:  J R Gavin; J Roth; D M Neville; P de Meyts; D N Buell
Journal:  Proc Natl Acad Sci U S A       Date:  1974-01       Impact factor: 11.205

9.  The glucose receptor. A defective mechanism in diabetes mellitus distinct from the beta adrenergic receptor.

Authors:  R P Robertson; D Porte
Journal:  J Clin Invest       Date:  1973-04       Impact factor: 14.808

10.  Uniphasic insulin responses to secretin stimulation in man.

Authors:  R L Lerner; D Porte
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

View more
  3 in total

1.  Type II diabetes mellitus.

Authors:  M B Davidson
Journal:  West J Med       Date:  1985-06

Review 2.  Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.

Authors:  Bo Ahrén; James E Foley
Journal:  Diabetologia       Date:  2016-02-19       Impact factor: 10.122

3.  Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?

Authors:  Bo Ahrén; James Edward Foley; Sylvie Dejager; Mouna Akacha; Qing Shao; Guenter Heimann; Markus Dworak; Anja Schweizer
Journal:  Diabetes Ther       Date:  2014-09-18       Impact factor: 2.945

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.